Hello, this is JNPMEDI.
The medical device industry is rapidly evolving with the emergence of AI-based diagnostic software, digital therapeutics (DTx), and digital medical products that qualify as medical devices. In practice, approvals of AI-based medical devices and global regulatory cases for digital medical devices continue to grow. Accordingly, the way medical device safety is managed is shifting toward a comprehensive approach that considers the entire product lifecycle.
In this context, medical device regulation is also expanding beyond a simple approval process into a system that manages risk across the entire product lifecycle. Theย โMedical Device Risk Management Guideline (Guidance for Applicants)โย recently released by the Ministry of Food and Drug Safety (MFDS) reflects this policy direction in response to changes in the industry.
Regulatory Changes Reflected in the Medical Device Risk Management Guideline
Source: Ministry of Food and Drug Safety (MFDS)
The MFDS Medical Device Risk Management Guideline is based on the international standard ISO 14971 (risk management for medical devices) and provides guidance on how to systematically manage risks throughout the development and operation of medical devices.
The key point of the guideline is that medical device safety management should not be limited to verification activities at the approval stage, but should extend across the entire product lifecycleโfrom design and development to manufacturing, real-world use, and post-market stages.
This reflects a regulatory direction that emphasizes the need for continuous risk management even after product launch, as the medical device industry becomes more complex and digital technologies continue to expand.
The Expansion of Digital Medical Devices and the Importance of Risk Management
In recent years, innovative products based on digital technologies have rapidly emerged in the medical device industry. Software-driven medical devices, such as AI-based diagnostic software and digital healthcare devices, present different risk factors compared to traditional hardware-based devices.
Factors such as changes in algorithm performance, data quality issues, and variability in real-world use environments can directly impact product safety. These characteristics make safety management systems for digital medical devices more complex.
Recent industry developments further highlight this trend, with continued approvals of AI-based medical devices and global certifications of digital medical devices underscoring the growing importance of robust risk management frameworks to ensure safety.
As a result, risk management is no longer merely a regulatory compliance processโit is becoming a core operational strategy for medical device companies to ensure product safety and build market trust.
How Real-World Data Is Reshaping Medical Device Safety Management
Source: AI-generated image
Another key shift in medical device risk management is the growing focus on data-driven safety management.
The guideline emphasizes the importance of continuously collecting and utilizing post-production information generated during actual product use. This information can be interpreted in connection with Real-World Data (RWD).
RWD refers to data collected as medical devices are used in real-world clinical settings. It can be used to identify potential risks at an early stage and to continuously evaluate product performance and safety in real-world environments. This is particularly important for AI-based and digital medical devices, where ongoing safety evaluation based on real-world data is critical.
This trend indicates that the paradigm of medical device safety management is expanding from approval-stage-centered risk management to continuous risk management that incorporates post-market information and data utilization.
Data-Driven Risk Management Strategies Medical Device Companies Must Prepare For
As the medical device industry becomes increasingly digital, risk management is also becoming more complex. Beyond risk analysis at the product development stage, it is becoming essential to establish systems that continuously manage and analyze data generated in real-world use after commercialization.
In particular, companies preparing for global market entry need to build risk management systems aligned with international standards, along with strategies to systematically manage post-market information and real-world data.
JNPMEDI supports medical device and pharmaceutical/biotech companies in establishing data-driven regulatory strategies, based on its experience in clinical trial operations, data management, and regulatory strategy development.
If you have any questions about medical device development, global regulatory strategy, or building data-driven safety management systems, we encourage you to contact JNPMEDI.
๐โโ๏ธ Contact JNPMEDI for inquiries
โป References
Ministry of Food and Drug Safety (MFDS). Medical Device Risk Management Guideline (Guidance for Applicants), February 2026.
Hello, this is JNPMEDI.
The medical device industry is rapidly evolving with the emergence of AI-based diagnostic software, digital therapeutics (DTx), and digital medical products that qualify as medical devices. In practice, approvals of AI-based medical devices and global regulatory cases for digital medical devices continue to grow. Accordingly, the way medical device safety is managed is shifting toward a comprehensive approach that considers the entire product lifecycle.
In this context, medical device regulation is also expanding beyond a simple approval process into a system that manages risk across the entire product lifecycle. Theย โMedical Device Risk Management Guideline (Guidance for Applicants)โย recently released by the Ministry of Food and Drug Safety (MFDS) reflects this policy direction in response to changes in the industry.
Regulatory Changes Reflected in the Medical Device Risk Management Guideline
Source: Ministry of Food and Drug Safety (MFDS)
The MFDS Medical Device Risk Management Guideline is based on the international standard ISO 14971 (risk management for medical devices) and provides guidance on how to systematically manage risks throughout the development and operation of medical devices.
The key point of the guideline is that medical device safety management should not be limited to verification activities at the approval stage, but should extend across the entire product lifecycleโfrom design and development to manufacturing, real-world use, and post-market stages.
This reflects a regulatory direction that emphasizes the need for continuous risk management even after product launch, as the medical device industry becomes more complex and digital technologies continue to expand.
The Expansion of Digital Medical Devices and the Importance of Risk Management
In recent years, innovative products based on digital technologies have rapidly emerged in the medical device industry. Software-driven medical devices, such as AI-based diagnostic software and digital healthcare devices, present different risk factors compared to traditional hardware-based devices.
Factors such as changes in algorithm performance, data quality issues, and variability in real-world use environments can directly impact product safety. These characteristics make safety management systems for digital medical devices more complex.
Recent industry developments further highlight this trend, with continued approvals of AI-based medical devices and global certifications of digital medical devices underscoring the growing importance of robust risk management frameworks to ensure safety.
As a result, risk management is no longer merely a regulatory compliance processโit is becoming a core operational strategy for medical device companies to ensure product safety and build market trust.
How Real-World Data Is Reshaping Medical Device Safety Management
Source: AI-generated image
Another key shift in medical device risk management is the growing focus on data-driven safety management.
The guideline emphasizes the importance of continuously collecting and utilizing post-production information generated during actual product use. This information can be interpreted in connection with Real-World Data (RWD).
RWD refers to data collected as medical devices are used in real-world clinical settings. It can be used to identify potential risks at an early stage and to continuously evaluate product performance and safety in real-world environments. This is particularly important for AI-based and digital medical devices, where ongoing safety evaluation based on real-world data is critical.
This trend indicates that the paradigm of medical device safety management is expanding from approval-stage-centered risk management to continuous risk management that incorporates post-market information and data utilization.
Data-Driven Risk Management Strategies Medical Device Companies Must Prepare For
As the medical device industry becomes increasingly digital, risk management is also becoming more complex. Beyond risk analysis at the product development stage, it is becoming essential to establish systems that continuously manage and analyze data generated in real-world use after commercialization.
In particular, companies preparing for global market entry need to build risk management systems aligned with international standards, along with strategies to systematically manage post-market information and real-world data.
JNPMEDI supports medical device and pharmaceutical/biotech companies in establishing data-driven regulatory strategies, based on its experience in clinical trial operations, data management, and regulatory strategy development.
If you have any questions about medical device development, global regulatory strategy, or building data-driven safety management systems, we encourage you to contact JNPMEDI.
๐โโ๏ธ Contact JNPMEDI for inquiries
โป References
Ministry of Food and Drug Safety (MFDS). Medical Device Risk Management Guideline (Guidance for Applicants), February 2026.